



UNIVERSIDADE ESTADUAL PAULISTA
"JÚLIO DE MESQUITA FILHO"
Campus de São José dos Campos
Instituto de Ciência e Tecnologia

EFEITO DO TRATAMENTO SINÉRGICO ENTRE PLASMA ATMOSFÉRICO FRIO E VITAMINA C NA CANDIDOSE EXPERIMENTAL INDUZIDA EM CAMUNDONGOS

Pós-doutoranda: Noala Vicensoto Moreira Milhan

Supervisora: Cristiane Yumi Koga-Ito

São José dos Campos

2024

RESUMO

Candida albicans é um fungo comensal, mas também oportunista, que pode causar doença na presença de fatores predisponentes, levando à candidose local ou invasiva. Estudos prévios in vitro e in vivo indicaram que o plasma frio em pressão atmosférica (CAP) pode exibir efeito antifúngico contra *C. albicans*, além de propriedades anti-inflamatórias. Outros estudos demonstraram efeito inibitório e modulação de fatores de virulência de *C. albicans* por vitamina C (Vit C), bem como propriedades anti-inflamatórias. Não foram detectados estudos sobre a associação de CAP e Vit C. O objetivo deste estudo é avaliar se a associação entre CAP e Vit C pode otimizar o efeito antifúngico exibido pelo CAP. Para isso, serão realizados procedimentos de imunossupressão e indução de candidose em dorso lingual de 35 camundongos, que serão aleatoriamente divididos em cinco grupos. 1) tratados com CAP (n = 7), 2) tratados com CAP e Vit C (n = 7), 3) tratados com vitamina C (n = 7), 4) tratados com nistatina (n=7) e 5) não tratados – grupo controle (n = 7). As diferentes modalidades de tratamento serão avaliadas por meio de análise clínica das lesões, no momento inicial do diagnóstico e previamente à eutanásia, análise microbiológica e microscópica das línguas, que serão hemisseccionadas após a eutanásia. A avaliação clínica levará em consideração escores associados a gravidade da lesão. Já a avaliação microbiológica será feita pela determinação da quantidade de *C. albicans* (UFC/grama) em macerados de língua. Por fim, nas análises microscópicas serão analisadas alterações epiteliais do dorso lingual e o grau de inflamação do tecido conjuntivo subjacente, além da contagem do número de hifas e leveduras da superfície epitelial de diferentes áreas do fragmento. Os dados obtidos serão submetidos ao teste estatístico mais apropriado, de acordo com a distribuição amostral ($p < 0.05$).

Palavras chave: Plasma frio em pressão atmosférica; Vitamina C; Candidose

1. INTRODUÇÃO

A Candidose Oral (CO) é uma doença bucal comum causada pelo fungo *Candida* spp. *C. albicans* é a espécie mais prevalente, sendo responsável por mais de 95% dos casos. Este fungo é um microrganismo comensal que habita a boca, o trato gastrointestinal e reprodutivo em mais de 80% da população (Vila et al., 2020). No entanto, *C. albicans* também é um patógeno oportunista que pode proliferar e causar doença na presença de fatores predisponentes (Singh et al., 2014; Vila et al., 2020).

Fatores locais, como higiene inadequada, uso ininterrupto de próteses, trauma na mucosa causado por próteses mal ajustadas, corticoterapia tópica, tabagismo e disfunção salivar, predispõe ao desenvolvimento de CO. Fatores sistêmicos também podem contribuir para a transição da condição comensal para a patogênica. Dentre esses fatores estão a terapia imunossupressora, a quimiorradiação, o uso de antibióticos de amplo espectro, a imunossenescência, as deficiências nutricionais e até mesmo disfunções endócrinas (Singh et al., 2014; Vila et al., 2020).

A capacidade de aderir às superfícies epiteliais orais, formar biofilmes e evadir os mecanismos de defesas do hospedeiro são fatores de virulência da *C. albicans* que contribuem para a CO (Vila et al., 2020). Clinicamente, as lesões podem apresentar-se como placas brancas removíveis à raspagem (candidose pseudomembranosa), manchas vermelhas (candidose eritematosa aguda ou crônica e queilite angular) e placas brancas aderentes (candidose hiperplásica crônica) (Lewis and Williams, 2017). Os achados microscópicos podem variar de acordo com a apresentação clínica e o grau de imunossupressão do indivíduo. Em geral, há penetração de hifas na superfície do epitélio, que geralmente apresenta exocitose e formação de microabscessos. O tecido conjuntivo apresenta reação imunológica com infiltrado inflamatório subepitelial caracterizado pela presença de macrófagos, linfócitos, granulócitos, além

hiperemia. Em indivíduos imunocomprometidos é esperada uma extensão mais profunda das hifas, além de redução do infiltrado inflamatório no tecido conjuntivo (Reichart et al., 2000).

O tratamento geralmente consiste no uso tópico ou sistêmico de agentes antifúngicos. Existem quatro tipos de antifúngicos com diferentes modos de ação e alvos, I) Polienos - ruptura das membranas celulares dos fungos (nistatina e anfotericina); II) Azóis - inibição da síntese de ergosterol (fluconazol e itraconazol); III) Equinocandinas – inibição das enzimas β -1,3 D-glucano sintetase (caspofungina); IV) Análogos da pirimidina - grupo que interfere na síntese do RNA e na replicação do DNA (flucitosina) (Costa-de-oliveira and Rodrigues, 2020; Lewis and Williams, 2017). As duas primeiras classes têm sido utilizadas para tratar CO; no entanto, o uso de polienos geralmente é limitado à administração tópica devido à má absorção através do intestino. O uso tópico também apresenta limitações pela dificuldade de manutenção de níveis adequados do medicamento no meio bucal. Diferentemente, azóis como fluconazol e itraconazol podem ser administrados sistemicamente, uma vez que são bem absorvidos pelo intestino. Entretanto, esses agentes apresentam interação medicamentosa com a varfarina (agente anticoagulante) e estatinas (inibidores da HMG-CoA redutase) (Lewis and Williams, 2017), não sendo adequados para paciente que utilizam essas medicações. Além disso, a resistência aos agentes antifúngicos é um assunto que tem emergido nos últimos anos (Costa-de-oliveira and Rodrigues, 2020; Lewis and Williams, 2017).

Diferentes mecanismos de resistência foram descritos para *C. albicans* de acordo com a classe antifúngica. Contra azóis, que representam agentes antifúngicos comumente utilizados, *C. albicans* pode atuar diminuindo a concentração do fármaco, alterando a enzima alvo, diminuindo a afinidade ao sítio de ligação, regulando positivamente a enzima alvo e na superexpressão de bombas de efluxo da membrana celular (Costa-de-oliveira and Rodrigues, 2020). Nesse contexto, tratamentos alternativos, que poderiam reduzir a frequência de

utilização dos agentes antifúngicos convencionais, têm sido investigados para tratar infecções antifúngicas na última década, incluindo a combinação de terapias (Fuentefria et al., 2018).

O plasma é conhecido como o quarto estado da matéria, o mais prevalente no universo. É uma mistura de moléculas fixas e móveis, átomos, elétrons e íons em temperaturas e densidades variadas (McCombs e Darby, 2010). O plasma pode ser produzido artificialmente e é utilizado para diversos fins industriais, como elementos eletrônicos. Esta tecnologia abrange dois grandes grupos, plasma térmico e plasma frio. O primeiro é útil para processos de fundição, incluindo síntese química ou indústria metalúrgica. Por outro lado, o plasma de pressão atmosférica frio (CAP) pode ter sido usado em materiais sensíveis ao calor para descontaminação biológica (López et al., 2019) e para aplicações biomédicas. Duas fontes de CAP têm sido comumente utilizadas no campo biomédico: descarga de barreira dielétrica (DBD) e jato de plasma de pressão atmosférica sem equilíbrio (NAPPJ) (Laroussi, 2020).

Além das propriedades antimicrobianas, o CAP pode apresentar efeito anti-inflamatório, contribuir para a cicatrização de feridas e até mesmo no tratamento do câncer (Braný et al., 2020). Dentre os mecanismos de ação do CAP, destaca-se a geração de espécies reativas de oxigênio e nitrogênio, que alteram a membrana celular das bactérias (Brun et al., 2018). As espécies reativas geradas pelo CAP também demonstraram ser eficazes contra fungos. Os possíveis efeitos do CAP nas células fúngicas são perda de permeabilidade e extravasamento celular, destruição de proteínas celulares, apoptose celular, fragmentação com liberação de DNA e deformação da ponta do micélio (Misra et al., 2019).

Estudos prévios demonstraram que o CAP apresenta propriedades antifúngicas contra *C. albicans* (Aparecida Delben et al., 2016; Borges et al., 2018; He et al., 2020). Observou-se *in vitro* que o jato de plasma operado com hélio, a uma distância de 1,5 cm, reduz a viabilidade de biofilmes de *C. albicans* após 5

minutos de exposição. Além disso, o CAP foi capaz de reduzir a invasão tecidual de *C. albicans* em modelo in vivo de candidose experimental (Borges et al., 2018).

A possibilidade de otimizar o tratamento com plasma, diminuindo seu tempo de exposição e/ou melhorando seu efeito é desejável. A Vit C, também conhecida como ácido ascórbico, é o mais poderoso agente antioxidante da pele com propriedades de formação de colágeno e clareamento cutâneo, o que confere a este composto uma ampla gama de aplicações clínicas (Al-Niaimi and Chiang, 2017). Devido ao seu efeito antioxidante, tem sido avaliado para diversas condições, como doenças inflamatórias (Lee et al., 2021; Yussif et al., 2016) e microbianas (Van Hauwenhuyse et al., 2014; LA et al., 2009), bem como para tratamento de câncer, quando utilizada em altas concentrações (Mussa et al., 2022).

Um estudo prévio demonstrou que o pré-tratamento com vit C aumenta o efeito bactericida do CAP contra biofilmes de *Staphylococcus epidermidis*, *Escherichia coli* e *Pseudomonas aeruginosa* (Helgadóttir et al., 2017). Até o momento, a associação entre Vit C e plasma para o tratamento da candidose não foi relatada na literatura. No entanto, o efeito isolado da vitamina C sobre *C. albicans* foi previamente investigado. Os autores observaram que o ácido ascórbico diminuiu a virulência e a patogenicidade de *C. albicans*, interferindo na transição levedura-hifa (LA et al., 2009). Outros autores demonstraram que a Vit C pode atuar em *C. albicans* dependente de Hsp90, no que diz respeito ao regulador transcricional Upc2. A vitamina bloqueou o crescimento de hifas, dependentes de GdA, restaurando os níveis normais de ergosterol, dependentes de Upc2 (Van Hauwenhuyse et al., 2014). Curiosamente, outro estudo demonstrou que a concentração de 90 mM de ascorbato é capaz de matar *C. albicans*. Entretanto essa eficácia foi dependente de temperatura, oxigenação, disponibilidade de fontes de energia, meio de crescimento e fase de crescimento (Avci et al., 2016).

No que diz respeito às propriedades anti-inflamatórias, a Vit C reduziu níveis de espécies reativas de oxigênio e inibiu a ativação de MAPKs, bem como a expressão de NF- κ B, AP-1 e IL-8 em células respiratórias humanas estimuladas com ácaros do pó doméstico (HDM) (Lee et al., 2021). Em outro estudo, a Vit C diminuiu a produção de espécies reativas de oxigênio, TNF- α e IL-6 em macrófagos desafiados por lipopolissacarídeos (LPS) e concomitantemente tratados por 24 horas com Vit C (100 nM). Recentemente, nosso grupo de pesquisa observou, de forma inédita, que o tratamento com Vit C induz propriedades anti-inflamatórias em queratinócitos desafiados com *C. albicans*, com redução da expressão gênica de IL-8 e IL-1 β , e uma tendência de redução de outros marcadores pró-inflamatórios (dados ainda não publicados).

Estudo in vivo, que injetou a Vit C no periodonto de animais com doença periodontal e diabetes, observou que o tratamento com esse componente pode ser benéfico para reduzir os níveis de MMP-8 gengival, o estresse oxidativo, a inflamação e o acúmulo de produtos de glicação avançada (AGEs) no tecido periodontal. Dessa forma concluíram que vit C é um agente imunomodulador e antioxidante promissor, que poderá ser aplicado localmente no tratamento da periodontite para reduzir os efeitos adversos do diabetes nos tecidos periodontais (Toraman et al., 2020). Adicionalmente, estudo clínico que avaliou a ação local de Vit C injetada em gengiva, observou que esse tratamento foi capaz de reduzir vários graus de inflamação gengival crônica (Yussif et al., 2016). Esses achados indicam que a administração injetável de Vit C pode ser uma alternativa para tratamentos de ação local em mucosa oral, o que abre perspectivas para novos estudos com essa abordagem. Essa forma de administração da vitamina demonstra-se promissora uma vez que o ambiente bucal não permite a manutenção prolongada de tratamentos tópicos na área de interesse.

Atualmente, existe um grande apelo por tratamentos alternativos que possam restringir a utilização, e consequentemente a resistência aos antibióticos. Da mesma forma, a otimização de tratamentos alternativos também se faz

necessária no contexto de doenças fúngicas. Com base nos achados abordados anteriormente, indicando que a Vit C pode apresentar propriedades antifúngicas e anti-inflamatórias, bem como otimizar efeitos bactericidas gerados pelo CAP, levantamos a hipótese de que a Vit C pode também potencializar o efeito benéfico do CAP em candidose experimental em modelo murino.

2. OBJETIVOS

O objetivo geral desse estudo é avaliar o efeito do tratamento sinérgico entre Vit C e CAP na candidose experimental induzida em modelo murino. Para alcançar o objetivo geral, os objetivos específicos serão:

- a) Analisar clinicamente as lesões de candidose bucal antes e após os tratamentos;
- b) Quantificar *C. albicans* (CFU/g) nas línguas, maceradas após a eutanásia;
- c) Avaliar microscopicamente as alterações epiteliais, a resposta inflamatória no tecido conjuntivo e o número de hifas e leveduras na superfície do epitélio.

3. MATERIAIS E MÉTODOS

3.1 Cepa e condições de crescimento microbiológico

Nesse estudo será utilizado uma cepa de referência, obtida de lesões de candidose (ATCC 18804). Os microrganismos serão cultivados em ágar Sabouraud dextrose por 24 horas a 37 °C, em aerobiose. Para a obtenção dos inóculos, que serão utilizados nos animais, serão realizadas suspensões de *C. albicans* em solução fisiológica estéril (NaCl 0,9%) em concentração de 10^8 UFC/ml, com auxílio de espectrofotômetro (λ : 530 nm; DO: 0,138). Os inóculos serão sempre preparados poucos minutos antes da inoculação nos animais, para que a viabilidade fúngica seja preservada.

3.2 Características do jato de plasma

Será utilizado equipamento de jato de plasma operado em baixa temperatura sob pressão atmosférica (CAP), gerado por um circuito elétrico bivolt (110/220 V) dentro de um cilindro com 11 cm de comprimento e 7 cm largura. Esse equipamento apresenta eletrodo de alta frequência com fonte de tensão pulsada. Será operado com gás hélio (He, Air Liquide, Brasil) exibindo 99,9% de pureza e vazão controlada de $2,0 \pm 0,1$ SLM (Litros por minuto) por controlador digital (N100 Horiba STEC).

3.2 Procedimentos e grupos experimentais

A metodologia de indução da candidose oral será baseada em alguns trabalhos prévios (Borges et al., 2018; Rossoni et al., 2015). Trinta e cinco camundongos machos (*Mus musculus* Swiss) de aproximadamente 40 g serão randomicamente divididos em 5 grupos: 1) tratados com CAP (n = 7), 2) tratados com CAP e Vit C (n = 7), 3) tratados com Vit C (n = 7), 4) tratados com nistatina (n = 7) e 5) não tratados – grupo controle (n = 7).

Todos os animais serão imunossuprimidos com metilprednisolona (Depro-Medrol; Pfizer) por via intraperitoneal na concentração de 100 mg/Kg de peso corporal, durante 4 dias intercalados. A inoculação com *C. albicans*, também abrangendo todos os animais, será realizada 2 vezes, em dias intercalados com as imunossupressões. Para isso, os animais serão sedados por via intraperitoneal com Cetamina 10% (Dopalen, 100 mg/kg) e Xilazina 2% (Anasedan, 10mg/kg). Então swabs embebidos em suspensão de *C. albicans* ATCC18804 (1×10^8 células/mL) serão mantidos em contato com o dorso da língua do animal durante 3 minutos. Três dias após a última inoculação, os animais serão examinados para o diagnóstico clínico das lesões. Os camundongos serão mantidos em mini-isoladores de rack ventilado com temperatura e luz controladas (22 °C; ciclo claro/escuro de 12/12h), receberão

alimentação padrão e água *ad libitum* acrescida de tetraciclina (Terramicina – Pfizer, 0,83 mg/ml).

Os camundongos serão submetidos ao tratamento com CAP duas vezes em um período de 48 horas, sendo que o primeiro tratamento será realizado 24 horas após o diagnóstico clínico da lesão. Os grupos tratados com CAP serão expostos ao jato de plasma durante 5 minutos, em dois sítios diferentes do dorso lingual, envolvendo o terço mediano anterior e posterior. Será mantida a distância de 1,5 cm entre a saída do aparato e a língua do animal. Os camundongos do grupo Vit C serão submetidos a injeções locais na mucosa com o composto, na concentração de 100 mg/kg. Já os animais do grupo CAP + Vit C receberão o tratamento com CAP, como descrito anteriormente, e injeções locais em mucosa de vitamina C (100 mg/kg), nas mesmas áreas tratadas pelo CAP, englobando o terço mediano anterior e posterior. Os tratamentos com CAP e Vit C serão realizados sob sedação. A simulação do tratamento da vitamina C, pela administração do veículo (água destilada) de forma injetável, será realizada nos grupos sem Vit C, assim como a simulação do procedimento do plasma (apenas gás), será executada nos grupos sem o CAP.

Já os animais do grupo nistatina, receberão 100 µL de suspensão de nistatina (100.000 UI/mL), em dorso de língua na região anterior, e 100 uL em dorso de língua na região posterior, por 2 dias. Os animais serão eutanasiados por excesso de anestésico, 24 horas após o último tratamento. O quadro 1 resume as etapas do experimento.

DIA	Evento
Dia 1	Imunossupressão
Dia 2	Infecção
Dia 3	Imunossupressão
Dia 4	Infecção
Dia 5	Imunossupressão
Dia 6	*
Dia 7	Diagnóstico e análise clínica da lesão
Dia 8	Tratamento
Dia 9	Tratamento
Dia 10	Análise clínica da lesão e eutanásia

Quadro 1: Esquema de execução do experimento

3.3 Avaliação clínica das lesões

Para avaliação clínica das lesões, previamente e posteriormente ao tratamento, as línguas serão observadas nos dias 7 e 10 do experimento. Com auxílio de uma lupa, as lesões serão minuciosamente observadas. Escores clínicos serão determinados com base em estudo prévio (Rossoni et al., 2015). Serão atribuídas pontuações de 0 a 4. Dessa forma, 0 corresponderá a dorso língua normal; 1: placas brancas/pseudomembranas em menos de 20% da

superfície; 2: placas brancas/pseudomembranas entre 21% e 90% da superfície; 3: placas brancas/pseudomembranas em mais de 91% da superfície; e 4: pseudomembranas espessas cobrindo mais de 91% da superfície do dorso lingual.

3.4 Análise microbiológica

Após a eutanásia as línguas serão hemisseccionadas, pesadas e a partes destinadas à análise microbiológica serão maceradas em solução salina estéril (NaCl 0,9%). Serão então realizadas diluições seriadas e o conteúdo semeado em ágar Sabouraud Dextrose acrescido de cloranfenicol. Posteriormente, a quantidade de *C. albicans* será determinada em CFU/g (Borges et al., 2018)

3.5 Avaliação microscópica

As línguas hemisseccionadas destinadas a análise microscópica serão fixadas em solução de formalina 10%, submetidas ao processamento histológico de rotina, e embebidas em parafina. Secções semi-seriadas de 5 micrômetros serão obtidas e coradas por HE (hematoxilina-eosina) para análise de alterações inflamatórias epiteliais e alterações inflamatórias no tecido conjuntivo.

Coloração de PAS (ácido periódico de Schiff) também será realizada para avaliar o grau de invasão do epitélio de dorso lingual por hifas e leveduras de *C. albicans*. Serão avaliados 21 campos histológicos de 2 cortes por animal, totalizando 42 campos. As análises serão realizadas com objetiva de 40 X em microscópio óptico (Zeiss). Serão atribuídos os seguintes escores: 0: ausência de hifas; 1: 1-5 hifas; 2: 6-15 hifas; 3: 16-50 hifas e 4: mais de 50 hifas (Borges et al., 2018; Rossoni et al., 2015).

3.6 Análise estatística

Os dados obtidos nos ensaios serão analisados estatisticamente com auxílio do programa GraphPad Prism, versão 6 (GraphPad Software Inc., San

Diego, CA, USA). Será realizado teste de distribuição amostral, para verificação de normalidade, e seleção do teste estatístico mais apropriado. O nível de significância adotado será de 5%.

4. PLANO DE ATIVIDADES E CRONOGRAMA PARA O PERÍODO

Abaixo estão apresentados o plano de atividades e cronograma para sua execução.

Atividades	Mês 1	Mês 2	Mês 3	Mês 4	Mês 5	Mês 6	Mês 7	Mês 8
Pesquisa bibliográfica	X	X	X	X	X	X	X	X
Etapa experimental em biotério	X	X						
Processamento dos dados dos clínicos e microbiológicos		X	X					
Processamento histopatológico			X	X	X			
Análises microscópicas					X	X	X	
Relatório final							X	X

5. REFERÊNCIAS

Al-Niaimi F, Chiang NYZ. Topical Vitamin C and the Skin: Mechanisms of Action and Clinical Applications. J Clin Aesthet Dermatol 2017;10:14–7.

Aparecida Delben J, Evelin Zago C, Tyhovych N, Duarte S, Eduardo Vergani C. Effect of atmospheric-pressure cold plasma on pathogenic oral biofilms and in vitro reconstituted oral epithelium. PLoS One 2016;11:1–18.

<https://doi.org/10.1371/journal.pone.0155427>.

Avci P, Freire F, Banvolgyi A, Mylonakis E, Wikonkal NM, Hamblin MR. Sodium ascorbate kills *Candida albicans* in vitro via iron-catalyzed Fenton reaction: Importance of oxygenation and metabolism. *Future Microbiol* 2016;11:1535–47. <https://doi.org/10.2217/fmb-2016-0063>.

Borges AC, de Moraes Gouvêa Lima G, Mayumi Castaldelli Nishime T, Vidal Lacerda Gontijo A, Kostov KG, Koga-Ito CY. Amplitude-modulated cold atmospheric pressure plasma jet for treatment of oral candidiasis: In vivo study. *PLoS One* 2018;13:1–19. <https://doi.org/10.1371/journal.pone.0199832>.

Braný D, Dvorská D, Halašová E, Škovierová H. Cold atmospheric plasma: A powerful tool for modern medicine. *Int J Mol Sci* 2020;21. <https://doi.org/10.3390/ijms21082932>.

Brun P, Bernabè G, Marchiori C, Scarpa M, Zuin M, Cavazzana R, et al. Antibacterial efficacy and mechanisms of action of low power atmospheric pressure cold plasma: membrane permeability, biofilm penetration and antimicrobial sensitization. *J Appl Microbiol* 2018;125:398–408. <https://doi.org/10.1111/jam.13780>.

Costa-de-oliveira S, Rodrigues AG. *Candida albicans* antifungal resistance and tolerance in bloodstream infections: The triad yeast-host-antifungal. *Microorganisms* 2020;8. <https://doi.org/10.3390/microorganisms8020154>.

Fuentefria AM, Pippi B, Dalla Lana DF, Donato KK, de Andrade SF. Antifungals discovery: an insight into new strategies to combat antifungal resistance. *Lett Appl Microbiol* 2018;66:2–13. <https://doi.org/10.1111/lam.12820>.

Van Hauwenhuyse F, Fiori A, Van Dijck P, Van Hauwenhuyse F, Fiori A, Van Dijck P. Ascorbic acid inhibition of *Candida albicans* Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2. *Eukaryot Cell* 2014;13:1278–89. <https://doi.org/10.1128/EC.00096-14>.

He M, Duan J, Xu J, Ma M, Chai B, He G, et al. Candida albicans biofilm inactivated by cold plasma treatment in vitro and in vivo. Plasma Processes and Polymers 2020;17. <https://doi.org/10.1002/ppap.201900068>.

Helgadóttir S, Pandit S, Mokkaapati VRSS, Westerlund F, Apell P, Mijakovic I. Vitamin C pretreatment enhances the antibacterial effect of Cold Atmospheric Plasma. Front Cell Infect Microbiol 2017;7:1–8. <https://doi.org/10.3389/fcimb.2017.00043>.

LA K, R O, N M. Ascorbic acid modulates pathogenecity markers of Candida albicans. Int J Microbiol Res 2009;1:19–24. <https://doi.org/10.9735/0975-5276.1.1.19-24>.

Laroussi M. Cold Plasma in Medicine and Healthcare: The New Frontier in Low Temperature Plasma Applications. Front Phys 2020;8:1–7. <https://doi.org/10.3389/fphy.2020.00074>.

Lee AJ, Lim JW, Kim H. Ascorbic Acid Suppresses House Dust Mite-Induced Expression of Interleukin-8 in Human Respiratory Epithelial Cells. J Cancer Prev 2021;26:64–70. <https://doi.org/10.15430/JCP.2021.26.1.64>.

Lewis MAO, Williams DW. Diagnosis and management of oral candidosis. Br Dent J 2017;223:675–81. <https://doi.org/10.1038/sj.bdj.2017.886>.

López M, Calvo T, Prieto M, Múgica-Vidal R, Muro-Fraguas I, Alba-Elías F, et al. A review on non-thermal atmospheric plasma for food preservation: Mode of action, determinants of effectiveness, and applications. Front Microbiol 2019;10. <https://doi.org/10.3389/fmicb.2019.00622>.

Misra NN, Yadav B, Roopesh MS, Jo C. Cold Plasma for Effective Fungal and Mycotoxin Control in Foods: Mechanisms, Inactivation Effects, and Applications. Compr Rev Food Sci Food Saf 2019;18:106–20. <https://doi.org/10.1111/1541-4337.12398>.

Mussa A, Mohd Idris RA, Ahmed N, Ahmad S, Murtadha AH, Tengku Din TADAA, et al. High-Dose Vitamin C for Cancer Therapy. *Pharmaceuticals (Basel)* 2022;15. <https://doi.org/10.3390/ph15060711>.

Reichart PA, Samaranayake LP, Philipsen HP. Pathology and clinical correlates in oral candidiasis and its variants: A review. *Oral Dis* 2000;6:85–91. <https://doi.org/10.1111/j.1601-0825.2000.tb00106.x>.

Rossoni RD, Barbosa JO, Vilela SFG, Dos Santos JD, De Barros PP, De Cristina M, et al. Competitive interactions between *C. albicans*, *C. glabrata* and *C. krusei* during biofilm formation and development of experimental candidiasis. *PLoS One* 2015;10. <https://doi.org/10.1371/journal.pone.0131700>.

Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. *J Oral Maxillofac Pathol* 2014;18:S81-5. <https://doi.org/10.4103/0973-029X.141325>.

Toraman A, Arabaci T, Aytekin Z, Albayrak M, Bayir Y. Effects of vitamin c local application on ligature-induced periodontitis in diabetic rats. *Journal of Applied Oral Science* 2020;28:1–12. <https://doi.org/10.1590/1678-7757-2020-0444>.

Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A disease of opportunity. *Journal of Fungi* 2020;6:1–28. <https://doi.org/10.3390/jof6010015>.

Yussif NM, Abdul Aziz MA, Abdel Rahman AR. Evaluation of the Anti-Inflammatory Effect of Locally Delivered Vitamin C in the Treatment of Persistent Gingival Inflammation: Clinical and Histopathological Study. *J Nutr Metab* 2016;2016:1–8. <https://doi.org/10.1155/2016/2978741>.

Apêndice A – Resultados microbiológicos e de viabilidade celular

1. Determinação da concentração inibitória mínima (MIC) e fungicida mínima (CFM) do ácido ascórbico

Observou-se que nenhuma das concentrações avaliadas de ácido ascórbico (Vit C), possui atividade antimicrobiana, uma vez que a turvação do meio foi semelhante ao controle de crescimento (grupo apenas com microrganismos) (Figura 1).




Figura 1: Imagem representativa de uma microplaca de 96 poços, onde foi realizado ensaio para estabelecimento da MIC e CFM. Os poços ilustrados com a cor vermelha indicam o controle negativo (sem turvação), enquanto os demarcados pela cor amarela correspondem ao controle de crescimento (controle positivo). Os demais poços, de turvação semelhante ao controle de crescimento, correspondem às diferentes concentrações de Vit C na faixa de 0,35 mM a 180 mM

2. Análise do tratamento proposto em biofilmes de 24 e 48 h

A avaliação dos dados de UFC/mL, após tratamento de biofilmes de 24 h, indicou diferença estatística entre os grupos ($p < 0,0001$, teste Kruskal wallis) (Figura 2A). O tratamento apenas com o plasma por 2,5 min (CAP) promoveu mais de um log de redução ($P < 0.05$) para o grupo controle. Houve também redução estatisticamente significativa nos grupos em que foi realizado o pré-tratamento com Ácido ascórbico na concentração de 90 mM ou o tratamento com o veículo (dH_2O), seguidos da exposição

ao CAP. O grupo Ácido ascórbico + CAP foi o grupo que apresentou o menor número de colônias, com redução de dois logs e meio em relação ao controle, embora não tenha sido diferente do grupo CAP. Já os grupos tratados apenas com Ácido ascórbico exibiram número de colônias semelhante ao grupo não tratado. A concentração de 180 mM também foi avaliada isoladamente ou em associação com o CAP, mas devido a similaridade de resultados com a concentração de 90 mM, os dados não estão apresentados.

A análise dos dados de UFC/mL, em biofilmes de 48 h, demonstrou diferença estatística entre os grupos ($p < 0,0001$, teste Kruskal wallis) (Figura 2B). Tanto o grupo CAP quanto o grupo ácido Ascórbico + CAP reduziram o número de colônias ($p < 0,05$ e $p < 0,0001$, respectivamente). O grupo Ácido ascórbico (90 mM) + CAP foi o mais efetivo, tendo promovido uma redução de aproximadamente dois logs em relação ao grupo controle, embora não tenha mostrado diferença estatística para o grupo CAP. Já o tratamento apenas com a vitamina não reduziu o número de colônias, com resultado semelhante ao grupo não tratado.




Figura 2: Gráfico representativo das médias e desvios-padrão das unidades formadoras de colônia por mL (UFC/mL) após os tratamento em biofilmes de 24 (A) e 48 horas (B) de *C. albicans*. Teste Kruskal-Wallis, comparações múltiplas (Letras diferentes indicam diferença estatística).

3. Ensaio de viabilidade celular após tratamento com CAP

A análise da viabilidade de queratinócitos expostos ao CAP indicou que o tratamento não foi citotóxico, com viabilidade celular acima de 70%, após 5 minutos de tratamento, como pode ser observado abaixo (Figura 3).




Figura 3: Gráfico representativo das médias e desvios-padrão dos dados de viabilidade celular após exposição de queratinócitos orais ao CAP 5 min. A linha pontilhada indica o limite normativo de viabilidade celular (= 70%). Note que os tratamentos não foram citotóxicos.

Apêndice B – Manuscrito aceito para publicação na Future Microbiology, contendo dados de toxicidade e imunomodulação da vitamina C

Future Microbiology



**Ascorbic acid as a modulator of
inflammatory response against *Candida
albicans***

Journal:	<i>Future Microbiology</i>
Manuscript ID	FMB-2023-0188.R2
Manuscript Type:	Research Article
Keywords:	vitamin C, ascorbic acid, candidiasis, infection model, anti-inflammatory

SCHOLARONE™
Manuscripts

<https://mc04.manuscriptcentral.com/fm-fmb>

Ascorbic acid as a modulator of inflammatory response against *Candida albicans*

Noala Vicensoto Moreira Milhan ¹, Aline da Graça Sampaio ¹, Cristiane Yumi Koga-Ito* ¹, Angela Bruzzaniti* ³

**Contributed equally to the study*

¹*Department of Environmental Engineering and Sciences Applied in Oral Health Graduate Program, São Paulo State University (Unesp), Institute of Science and Technology, São José dos Campos, São Paulo, 12245-000, Brazil.*

² *Department of Biomedical and Applied Sciences, Indiana University School of Dentistry, Indianapolis, IN, 46202, USA*

Correspondence: milhan.noala@gmail.com (N.V.M.M.)

ABSTRACT

Aims: To evaluate the behavior of oral keratinocytes in the presence of Vitamin C (Vit C) and its anti-inflammatory potential. **Materials & Methods:** Oral keratinocytes were initially exposed to 0.1 to 2.5 mM of Vit C and the metabolic activity and cell migration were evaluated using MTS assay and Ibidi culture inserts, respectively. After, the cells were challenged with *Candida albicans* and inflammatory markers were analyzed by qPCR. **Results:** The treatment was not cytotoxic, and the highest concentrations increased the metabolic activity at 24 h. Vit C delayed the cell migration at 48 and 72 h. Interestingly, it downregulated the genes IL-8 and IL-1b. **Conclusion:** Vit C could be an interesting adjuvant to anti-fungal treatment due to its anti-inflammatory potential.

Plain Language Summary

Vitamin C, also known as ascorbic acid, is a vitamin commonly found in fruits and vegetables. It is popular for supporting our immune system, so is commonly taken as a supplement. We looked at the action of vitamin C on cells in the mouth and its potential to reduce inflammation in a fungal disease of the mouth - oral candidiasis. We showed that vitamin C is not toxic to cells of the mouth and may reduce inflammation in cells

infected by the fungus. This suggests that vitamin C could be used as a complementary therapy for oral candidiasis.

Key words: vitamin C; ascorbic acid; candidiasis; infection model; anti-inflammatory

First draft submitted: 22 Aug 2023; Accepted for publication: 8 Dec 2023; Published online: TBC

1. Introduction

Oral Candidiasis (OC) is an oral disease caused by *Candida* spp. *C. albicans* is the most prevalent species, which is responsible for more than 95% of OC cases. This fungus is a commensal microorganism that inhabits the mouth, gastrointestinal, and reproductive tracts in more than 80% of the population [1]. However, *C. albicans* is an opportunistic pathogen that can proliferate and cause disease in the presence of local and/or systemic predisposing factors [1,2].

The adherence to oral epithelial cells, ability to form biofilms, evasion from host's immune defenses and the capacity to invade and destroy host tissues are considered important virulence features of *C. albicans* [1]. Polyenes and azoles have been considered the main antifungal agents to treat OC, however, the use of polyenes usually is limited to topical delivery due to the poor absorption through the gastrointestinal tract. The topical use also presents

limitations because of difficulty in maintaining adequate levels of the drug in the oral environment. In contrast, azoles, such as fluconazole and itraconazole, may be administered systemically as they are well absorbed by the gastrointestinal tract. Despite this, these agents may present drug interactions with warfarin (anticoagulant agent) and statins (HMG-CoA reductase inhibitors) [3]. Moreover, the prevalence of antifungal resistance has increased significantly in recent years [3,4].

Different mechanisms of resistance have been described for *C. albicans* according to the antifungal class. Against azoles, *C. albicans* may act decreasing drug concentration, changing target enzyme, decreasing affinity to the binding site, upregulating the target enzyme and promoting the overexpression of cell membrane efflux pumps [4]. In attempt to solve these problems, alternative treatments have been investigated to treat antifungal infections in the last decade, including the combination of therapies [5].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

70 Vit C is a powerful antioxidant agent [6] and has been evaluated for many conditions,
71 such as infectious diseases [7,8]. The effect of Vit C on *C. albicans* was previously investigated
72 [8]. The authors observed that Vit C decreased the virulence and pathogenicity of *C. albicans*
73 interfering with yeast-to-hypha transition. Van Hauwenhuyse et al. showed that Vit C may act
74 in Hsp90-dependent *C. albicans* concerning transcriptional regulator Upc2. Vit C blocked GdA-
75 dependent elongated growth by restoring normal ergosterol levels in a Upc2-dependent
76 manner
77 [7]. Interestingly, another study demonstrated that the concentration of 90 mM of Vit C can kill
78 *C. albicans*. This effectiveness was dependent on temperature, oxygenation, availability of
79 energy sources, growth media and growth phase [9].

80 Other studies have also indicated that Vit C may exert local anti-inflammatory
81 properties, reducing ROS levels and inhibiting the activation of MAPKs, NF-κB, AP-1 and IL-
82 8 expression in human respiratory cells [10]. In a clinical study, Vit C was able to reduce various
83 degrees of chronic gingival inflammation [11]. Additionally, it has been considered the most
84 powerful antioxidant agent of the skin with neocollagenesis and skin-lightening properties,
85 which give to this compound a large range of clinical applications [6].

86 Considering the promising findings related to anti-inflammatory properties of Vit C as
87 well as the modulatory effects of Vit C on *C. albicans* virulence factors, we hypothesized that
88 Vit C could be an interesting adjunct treatment for OC. As far as we know, the effects of Vit C
89 on in vitro model of OC have not previously been explored. The current study evaluated the
90 effects of Vit C on oral keratinocytes, with respect to its viability/proliferation, migration
91 properties and anti-inflammatory potential in cells challenged with *C. albicans*.

92 **2. Material and methods**

93 **2.1 Cell culture**

94 Primary gingival keratinocytes (PGKs) from the American Type Culture Collection
95 (ATCC, PCS-200-014) were used in this study. The cells were cultured in Dermal Cell Basal
96 Medium (ATCC, PCS-200-030) supplemented with keratinocyte growth kit (ATCC, PCS-200-
97 040) and penicillin (100 U/mL). The cells were grown at 37°C in a humid environment with 5%
98 CO₂. The media was changed every 2-3 days and cells up to 5 passages were used for all the
99 assays.

100
101 **2.2 Cell viability/proliferation assay**

PGKs were cultured in 24-well plates at a density of 20×10^3 cells per well (500 μ L/well) and incubated at 37° for 24 h, when the treatments were performed. L-ascorbic acid (Sigma-Aldrich) was initially diluted in distilled water to a concentration of 90 mM and then filtered through a syringe filter of 0.22 mm. Afterwards, the Vit C was diluted in the cell culture media to a final concentration of 2.5, 1.25, 0.6, 0.3 and 0.1 mM, and immediately placed in contact with the cells. Cell viability was evaluated after 3 and 24 h of treatment using the colorimetric metabolic assay MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; Promega Corp., CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay. Absorbance was measured at a wavelength of 490 nm by SoftMax Pro 6 software after 2 h of incubation. A control group (only cells and culture medium without Vit C) was performed under the same conditions and used as a normalizer. The test was carried out in two independent experiments (n=8). The cytotoxicity threshold was set at 70% according to previous studies [12,13].

2.3 Two-dimensional cell migration test (in vitro wound healing assay)

For this assay, high culture inserts with two chambers and a gap between them (Ibidi - μ -Dish 35mm; Cat. n°. 81176) were inserted in 4-well plates. PGKs were plated in the chambers at a density of 3×10^3 cells (75 mL) per chamber. The cells were cultured until reaching approximately 70% of confluence, when the inserts were removed. Subsequently, the cells were exposed to 0.1, 0.6, 1.2 mM of Vit C and the images of cells within the gap area were captured by microscopy (Leica DMI 4000B, Leica Microsystems) using Image-Pro Plus MDA, version 7.0 software. Images of the cellular migration into the gap areas were taken at 3, 24, 48 and 72 h of the starting treatment. Quantification of the distance between cells grown in the two chambers (wound area distance) was analyzed using the Wound Healing Size tool in the ImageJ/Fiji® plugin, as described by Arnedo et al. [14]. The assay was performed in two independent experiments (n=8). The treated groups were compared to control group, in which the cells were exposed only to culture medium.

2.4 Infection model

Before the infection, PGKs were plated in 24-well plates at a density of 1×10^5 cells per well (500 μ L/well) and incubated at 37°C for 24 h. In the same day, *C. albicans* (SC 5314) were cultured in Sabouraud Dextrose agar plates at 37°C for 24 h. For the infection, an inoculum of *C. albicans* at a density of 5×10^5 was prepared in Dermal Cell Basal Medium (ATCC, PCS-200-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

135 030) supplemented with keratinocyte growth kit (ATCC, PCS-200-040) and penicillin (100
136 U/mL) and inserted in the wells. After 1 h of the infection, the plates were centrifuged, the spent
137 culture medium was removed and Vit C solutions at the concentrations of 0.1, 0.6 and 1.2 mM
138 were added to the wells. Afterward, the plates were incubated for 6 h at 37°C and the lysate was
139 collected. To determine a suitable period of infection, the periods of 4 h and 24 h of infection
140 were also evaluated as pilot assays. For cell lysis, a lysis solution of RNAqueous™-Micro Total
141 RNA Isolation Kit (AM1931, Thermo Fisher Scientific) was used and the samples were stored
142 at -80°C.

19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

143
144 **2.5 qPCR analysis**
145 Total RNA was isolated using RNAqueous™- Micro Total RNA Isolation Kit (Thermo
146 Fisher Scientific, AM1931). The total RNA was treated with DNase I provided with the kit to
147 remove remnant genomic DNA in the samples. Complementary DNA (cDNA) was synthesized
148 using High capacity cDNA reverse transcription kit (Thermo Fisher Scientific, 4368813).
149 Quantitative real-time PCR (qPCR) was performed to quantify mRNA expression using
150 SYBR® green PCR Master Mix (Applied Biosystems, Warringtons, UK). The oligonucleotide
151 primer sequences for the pro-inflammatory (IL-8, GM-CSF, IL-1b, TNF-α, IL-6) and anti-
152 inflammatory (IL-10) genes can be observed in Table 1. All samples were run in the QuantStudio
153 7 flex detection system. The threshold cycle (Ct) for each test gene was normalized against the
154 18S housekeeping gene. The housekeeping gene was unaffected by the infection or treatment
155 with Vit C. The absolute mRNA values were calculated using the equation $\Delta Ct = Ct \text{ (gene of interest)} - Ct \text{ (housekeeping gene)}$.

43
44
45
46
47
48
49
50
51
52
53
54
55
56

157
158 **2.6 Statistical analysis**
159 The data were plotted and expressed as mean values and standard deviations (mean
160 $\pm$ SD). Statistical analysis was performed using the GraphPad Prism 9 software (GraphPad
161 Software, Inc. San Diego, CA, USA). Data were first analyzed regarding sample distribution.
162 Parametric data were analyzed using analysis of variance (one-way ANOVA, $\alpha = 0.05$) and
163 Tukey's post hoc test. The nonparametric data were compared by Kruskal-Wallis and Dunn's/
164 Dunnett's post hoc tests ($\alpha = 0.05$).

57

165
166 **3. RESULTS**

58
59
60

167 3.1 Vit C increases the metabolic activity of oral keratinocytes at 24 h of treatment in a
168 dose dependent manner.

1
2
3 169 After 3 h of treatment, the different concentrations of Vit C did not decrease the cell
4
5 170 viability to levels lower than the cytotoxicity threshold (70%), although 0.3 mM reduced cell
6
7 171 viability to a similar level (70.6%), with statistical difference in relation to the control group
8 172 (Dunn's multiple comparisons test, $p<0.001$). The other concentrations of Vit C (0.1, 0.6, 1.2
9
10 173 and 2.5 mM) showed more than 80% cell viability with no statistical difference for in relation
11
12 174 to the control group or among them ($p>0.05$, Dunn's multiple comparisons test) (Figure 1A).
13 175 After 24 h, Vit C maintained or increased the metabolic activity, depending on the concentration.
14 176 The treatment with 1.2 and 2.5 mM increased the cell viability/proliferation to 135% and 145%,
15
16
17 177 respectively, with statistical differences when compared control group (Tukey's multiple
18
19 178 comparisons test, $p<0.05$) (Figure 1B).
20 179
21
22 180 3.2 Vit C changes the migration properties of oral keratinocytes at 48 h and 72 h.
23
24 181 The analysis of the in vitro gap closure showed no statistical difference between treated
25
26 182 and control groups at 3 h and 24 h ($p>0.05$, one-way ANOVA test). However, statistical
27
28 183 differences were observed at 48 h and 72 h ($p<0.05$, one-way ANOVA and Kruskal-Wallis tests,
29 184 respectively). A delayed gap closure kinetic (migration property) was detected in the group
30 185 treated with 1.2 mM of Vit C that showed statistical differences in relation to control group at
31
32 186 48 h ($p<0.05$, Dunnett's multiple comparisons test) and 72 h ($p<0.05$, Dunn's multiple
33
34 187 comparisons test). The concentrations of 0.1 and 0.6 mM of Vit C were also statistically different
35 188 from control group at 48 h ($p<0.05$, Dunnett's multiple comparisons test) and 72 h ($p<0.05$,
36 189 Dunn's multiple comparisons test), respectively (Figure 2).
37
38
39 190
40 191 3.3 Vit C modulates the inflammatory response of oral keratinocytes against *C.*
41
42 192 *albicans*.
43
44 193 A range of different conditions were evaluated to find a suitable period of infection in
45 194 which the control and infection groups were statistically different indicating a pro-inflammatory
46
47 195 scenario. The period of 4 h was not sufficient to induce a pro-inflammatory response, as no
48
49 196 statistical differences could be observed between control (only culture medium – non-infected
50 197 cells) and infection groups. On the other hand, a period of 24 h of infection was very long, as
51 198 most of the cells had died (data not shown).
52
53
54 199 An infection period of 7 h showed optimal conditions of infection, as can be observed in
55
56 200 Figure 3. Statistical differences between control and infection group were observed for the genes
57 201 IL-8, GM-CSF, and IL-1b ($p<0.05$, Tukey's multiple comparisons test). Vit C showed an anti-
58
59 202 inflammatory effect with downregulation of genes IL-8 after treatment with 0.1 and 1.2 mM of
60

1
2
3 203 Vit C and IL-1b after treatment with 1.2 mM of Vit C. These treatments showed statistical
4
5 204 differences for infection group ($p<0.05$, Tukey's multiple comparisons test). The analysis of the
6
7 205 gene GM-CSF showed no statistical differences between infection and Vit C groups ($p>0.05$,
8 206 Tukey's multiple comparisons test), although lower means of absolute mRNA have been
9
10 207 observed in the treated groups, mostly at concentration of 0.1 mM of Vit C, which also was not
11
12 208 statistically different from negative control group (Figure 3, A, B, C).
13 209 No statistical differences were observed between groups for IL-6 and TNF- α genes,
14 210 although the infection group showed a tendency of upregulation while the treated groups
15
16 211 demonstrated a tendency of downregulation ($p>0.05$, Tukey's multiple comparisons test) (Figure
17
18 212 3, D and E). The anti-inflammatory gene IL-10 was not expressed at a detectable level by the
19 213 cells (data not shown).
20
21 214
22
23 215 **4. Discussion**
24
25 216 The search for new anti-fungal treatments has emerged in the last decades, including the
26
27 217 combination of therapies [5,15]. Vit C has currently been evaluated for multiple purposes
28 218 [16,17] , including its action as an anti-inflammatory agent [18] . The aim of the current study
29 219 was to evaluate Vit C as a possible modulator of treatment for oral candidiasis. For this, the
30
31 220 potential effects of Vit C on the metabolic activity and migration of oral keratinocytes were first
32
33 221 evaluated. After, an in vitro infection model in which the cells were challenged with *C. albicans*
34 222 and treated with Vit C. was performed to evaluate the anti-inflammatory potential of Vit C. Oral
35
36 223 keratinocytes were chosen for this study because they are the first line of defense against
37
38 224 candidal infection working as a physical barrier in the oral cavity [19].
39
40
41 225 The MTS assays indicated that Vit C did not reduce the cell viability below the
42 226 acceptable cytotoxicity threshold (70%) after the first hours of exposure. Additionally, the
43 227 higher concentrations stimulated the cells after 24 h, as indicated by the marked increase in
44
45 228 metabolic activity, an indicator of cell viability/proliferation. It is well known that keratinocytes
46
47 229 can express two different transporters, which are responsible for Vit C uptake, the sodium-
48 230 dependent vitamin C transporter 1 (SVCT1) and 2 (SVCT2) [20,21]. A previous study proposed
49
50 231 a biphasic role of Vit C according to SVCT-2 expression in intestinal cancer cells. High SVCT2
51
52 232 expression is probably related with a pro-oxidant effect culminating in cell death while low
53 233 SVCT2 expression may be related with an antioxidant effect and high cell viability/proliferation.
54
55 234 The authors observed that the decrease in cell viability is inversely proportional to SVCT2
56
57 235 expression [22]. In the current study with PGKs cells, the higher metabolic activity observed
58
59 236 after 24 h of exposure could indicate an antioxidant effect and low SVCT2 expression.
60

Candidal infection often induces non-ulcerative lesions. However, in critically ill patients, this infection is commonly responsible for chronic oral ulcers [19] in which the properties of proliferation and migration of the cells are crucial for tissue repair. Keratinocytes are able to undergo an epithelial-to-mesenchymal transition, which gives them an ability to migrate toward each other by reformulating cell–cell and cell–extracellular binding. Thus, it is possible to measure the re-epithelialization stage of wound healing [23]. Therefore, we performed an in vitro migration/wound closure assay to analyze the in vitro role of Vit C in the migration of the oral keratinocytes. Our measurements indicate that Vit C delayed the wound healing kinetic after 48 h and 72 h, although Vit C did not significantly interfere with wound healing process at 3 h and 24 h. A previous study that evaluated primary epidermal keratinocytes wound healing for 24 h observed that 4.4 µg/mL of Vit C did not change the cellular gap closure after this period [24], similarly to our study after 24 h. Other studies using two-dimensional monolayer models of cells have indicated good ability of Vit C to promote in vitro wound healing, however these studies focused on different cell types [25,26]. The reasons by which vitamin C delayed the cell migration at 48 h and 72 h in our hands is still unclear and need to be investigated. It is noteworthy that this assay was not performed in the presence of infection, due to the high pathogenicity of *C. albicans* strain after 24 hours of infection, which represents a limiting factor of this in vitro study.

According to previous findings, Vit C can regulate epidermal differentiation via activation of protein kinase C (PKC). Additionally, it has been shown to protect keratinocytes against oxidative stress, particularly during the inflammatory phase of wound repair, by the improvement of the hydrophilic antioxidant status inside the cells [27]. In our study, the anti-inflammatory potential of Vit C on PGK cells challenged with *C. albicans* was investigated through the analysis of genes related to the inflammatory response. The model of infection was validated after 7 h of PGK-fungi contact via the upregulation of IL-8, GM-CSF, and IL-1b genes. These are pro-inflammatory markers that usually become upregulated when oral epithelial cells are infected with *C. albicans*, especially during direct physical contact and the germination of yeast into hyphae [28–31]. Vit C showed an anti-inflammatory potential in the conditions of this study, as observed by the statistical downregulation of IL-8 and IL-1b, and a dose-dependent downregulation tendency of the pro-inflammatory genes GM-CSF, TNF-a and IL-6.

Consistent with our findings, Vit C showed an anti-inflammatory property in UVB-damaged keratinocytes suppressing the inflammatory response via the downregulation of IL-8 and MCP-1 [32]. Respiratory epithelial cells (H292) challenged with house dust-mites (HDM) and treated with 100 or 200 mM Vit C were reported. The challenge enhanced ROS levels,

1
2
3 271 increased IL-8 expression and activated the signaling pathways MAPKs, NF- κ B, and AP-1.
4
5 272 Interestingly, the treatment with Vit C decreased ROS levels. Additionally, it inhibited
6
7 273 activation of MAPKs, NF- κ B and AP-1 and downregulated the expression of IL-8 [10]. Other
8 274 studies that have investigated different doses of Vit C also indicated that this vitamin could
9
10 275 inhibit multiple pathways related to the activation of NF- κ B transcription factor [33–35].
11
12 276 Cárcamo et al., 2002 pointed out the importance of the ROS in the GM-CSF signaling response
13 277 and showed that the treatment with Vit C can downmodulate GM-CSF signaling responses in
14 278 human monocytic (U937), kidney (293T) and human myeloid cells (HL-60) at intracellular
15
16
17 279 concentrations of 5 mM [36]. In another study, Vit C decreased lipopolysaccharide (LPS)-
18
19 280 induced ROS, TNF- α and IL-6 production in macrophages challenged and treated for 24 h with
20 281 LPS and Vit C (100 nM), respectively [37]. In the present study, a dose-dependent
21 282 downregulation tendency of the pro-inflammatory genes GM-CSF, TNF- α and IL-6 was
22
23 283 observed after 6 h of treatment. Due to the high virulence of the strain used in our model
24 of
25 284 infection, it was not possible to evaluate if statistical significance would be obtained after 24 h
26 285 of exposure to Vit C. Nevertheless, the anti-inflammatory potential of Vit C was seen after 6 h
27
28 286 of treatment, resulting in the downregulation IL-8 and IL-1b.

31 287 Considering the activation of NF- κ B transcription factor in the inflammatory response
32 288 against *C. albicans* [38,39], Vit C may be inhibiting some signaling pathway related to NF- κ B,
33 289 resulting in the anti-inflammatory effects observed in this study. Corroborating our hypothesis,
34
35 290 these findings indicate that Vit C could be an interesting adjuvant to anti-fungal treatment and
36 291 highlight the importance of future in vitro and in vivo studies in this approach.
37
38
39
40

41 293 **5. Conclusion**

43 294 Vit C presents an anti-inflammatory effect on oral keratinocytes challenged with *C.*
44 295 *albicans*, which suggests that it could be an interesting adjunct for the treatment of oral
45 296 candidiasis. It is important to emphasize that this was an in vitro study with its limitations, and
46
47 297 the interference of Vit C in wound repair in cases of candidiasis should be investigated in future
48
49 in vivo models.

52 300 **Summary points**

- 54 301 • Vitamin C is an antioxidant agent that has been investigated for the treatment of different
55 302 microbial and inflammatory conditions.
56
57 303 • Previous studies demonstrated that this compound may present modulatory effects on *C.*
58 304 *albicans* virulence factors.

- Alternative methods to reduce the use of antifungals agents are desired.
- This study evaluated for the first time the effects of Vit C on in vitro model of oral candidiasis.
- Vit C increased the metabolic activity of the cells at 24 h and delayed the cell migration at 48 and 72 h.
- Vit C downregulated the pro-inflammatory genes IL-8 and IL-1b.
- The data indicated that Vit C could be an interesting adjunct for the treatment of oral candidiasis.

Figure and Table Legends

Table 1: Oligonucleotide primer sequences

Figure 1: Cell viability of oral keratinocytes after Vit C exposure for 3 h (A) and 24 h (B). Bars represent mean and SD values after the treatments. The dotted line (red) corresponds to the toxicity threshold (ISO 10993-5). Different letters indicate statistical differences between groups (A, Kruskal-Wallis and Dunn's post hoc tests, $p<0.05$; B, one-way ANOVA and Tukey's post hoc test, $p<0.05$).

Figure 2: Analysis of cell migration or in vitro wound closure using oral keratinocytes (A) Mean data and SD error bars of the remaining scratch/gap area at 3, 24, 48 and 72 h. (B) Illustrations of the in vitro wound closure for each group at all the periods. The images were captured in an inverted microscope at 250X magnification. The asterisks (*) indicate statistical differences between control group and 0.1/1.2 mM of Vit C at 48 h and 0.6/1.2 mM of Vit C at 72 h (3, 24, 48h; one-way ANOVA and Dunnett's post hoc test, $p<0.05$), (72 h; Kruskal-Wallis and Dunn's post hoc tests, $p<0.05$).

Figure 3: Effect of infection with *Candida albicans* for 7 h and treatment with Vit C for 6 h on IL-8 (A), GM-CSF (B), IL-1b (C), IL-6 (D) and TNF- α (E) gene expression by oral keratinocytes. Bars represent mean and SD values after the different treatments. 18S was used as housekeeping gene. Different letters indicate statistical differences between groups (one-way ANOVA and Tukey's post hoc test, $p<0.05$).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

338

339 **Financial disclosure**

340 This work was supported by the São Paulo State Research Foundation (FAPESP)

341 [2022/04598-7; 2022/04723-6; 2019/05856-7] and by funds from the Indiana University

342 School of Dentistry. The authors have no other relevant affiliations or financial

343 involvement with any organization or entity with a financial interest in or financial

344 conflict with the subject matter or materials discussed in the manuscript apart from those

345 disclosed.

346

347 No writing assistance was utilized in the production of this manuscript.

348

349 **Competing interest disclosure**

350 The authors have no competing interests or relevant affiliations with any organization or entity

351 with the subject matter or materials discussed in the manuscript. This includes employment,

352 consultancies, honoraria, stock ownership or options, expert testimony, grants or patents

353 received or pending, or royalties.

354

355 **6. References**

356 Papers of special note have been highlighted as: • of interest; •• of considerable interest.

357 1. Vila T, Sultan AS, Montelongo-Jauregui D, Jabra-Rizk MA. Oral candidiasis: A

358 disease of opportunity. *J.Fungi*. 6(1), 1–28 (2020).

359 • Interesting review about oral candidiasis

360 2. Singh A, Verma R, Murari A, Agrawal A. Oral candidiasis: An overview. *J Oral*

361 *Maxillofac Pathol*. 18(Suppl 1), S81-5 (2014).

362 3. Lewis MAO, Williams DW. Diagnosis and management of oral candidosis. *Br*

363 *Dent J*. 223(9), 675–681 (2017).

364 4. Costa-de-oliveira S, Rodrigues AG. *Candida albicans* antifungal resistance and

365 tolerance in bloodstream infections: The triad yeast-host-antifungal.

366 *Microorganisms*. 8(2),154 (2020).

367 5. Fuentefria AM, Pippi B, Dalla Lana DF, Donato KK, de Andrade SF.

368 Antifungals discovery: an insight into new strategies to combat antifungal

369 resistance. *Lett Appl Microbiol*. 66(1), 2–13 (2018).

370 6. Al-Niaimi F, Chiang NYZ. Topical Vitamin C and the Skin: Mechanisms of

371 Action and Clinical Applications. *J Clin Aesthet Dermatol*. 10(7), 14–17 (2017).

372 7. Van Hauwenhuyse F, Fiori A, Van Dijck P. Ascorbic acid inhibition of candida

373 *albicans* Hsp90-mediated morphogenesis occurs via the transcriptional regulator

374 Upc2. *Eukaryot Cell*. 13(10), 1278–1289 (2014).

375 •• This study investigated Vitamin C mechanisms of action on *Candida*

376 *albicans* strains.

377 8. LA K, R O, N M. Ascorbic acid modulates pathogenecity markers of *Candida*

378 *albicans*. *Int J Microbiol Res*. 1(1), 19–24 (2009).

379 •• Interesting manuscript about Vitamin C modulatory effects on *Candida*

380 *albicans* strains.

381 9. Avci P, Freire F, Banvolgyi A, Mylonakis E, Wikonkal NM, Hamblin MR.

382 Sodium ascorbate kills *Candida albicans* in vitro via iron-catalyzed Fenton

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

reaction: Importance of oxygenation and metabolism. *Future Microbiol.* 11(12), 1535–1547 (2016).

•• This manuscript indicated that ascorbate may present antimicrobial effects against *Candida albicans* strains.

10. Lee AJ, Lim JW, Kim H. Ascorbic Acid Suppresses House Dust Mite-Induced Expression of Interleukin-8 in Human Respiratory Epithelial Cells. *J Cancer Prev.* 26(1), 64–70 (2021).

•• This study demonstrated in a different model of infection that vitamin C may present an anti-inflammatory effect.

11. Mohammed Ahmed Yussif N, Abdul-Waniss Mohammed Abdul-Aziz M, Reda Abdel Rahman A. Evaluation of the Anti-Inflammatory Effect of Locally Delivered Vitamin C in the Treatment of Persistent Gingival Inflammation: Clinical and Histopathological Study. *J Nutr Metab.* 2016, 2978741 (2016).

12. Jablonská E, Kubásek J, Vojtěch D, Ruml T, Lipov J. Test conditions can significantly affect the results of in vitro cytotoxicity testing of degradable metallic biomaterials. *Sci Rep.* 11, 6628 (2021).

13. Sampaio A da G, Chiappim W, Milhan NVM, Botan Neto B, Pessoa R, Koga-Ito CY. Effect of the pH on the Antibacterial Potential and Cytotoxicity of Different Plasma-Activated Liquids. *Int J Mol Sci.* 23(22), 13893 (2022).

14. Suarez-Arnedo A, Torres Figueroa F, Clavijo C, Arbeláez P, Cruz JC, Muñoz-Camargo C. An image J plugin for the high throughput image analysis of in vitro scratch wound healing assays. *PLoS One.* 15(7), e0232565 (2020).

15. Vitale RG. Role of antifungal combinations in difficult to treat candida infections. *J. Fungi* 7(9), 731 (2021).

16. Böttger F, Vallés-Martí A, Cahn L, Jimenez CR. High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer. *J. Exp. Clin. Cancer Res.* 40(1), 343 (2021).

17. Zylinska L, Lisek M, Guo F, Boczek T. Vitamin C Modes of Action in Calcium-Involved Signaling in the Brain. *Antioxidants.* 12(2), 231 (2023).

18. Aytekin Z, Arabaci T, Toraman A, Bayır Y, Albayrak M, Üstün K. Immune modulatory and antioxidant effects of locally administrated vitamin C in experimental periodontitis in rats. *Acta Odontol Scand.* 78(6), 425–432 (2020).

19. Lu SY. Oral candidosis: Pathophysiology and best practice for diagnosis, classification, and successful management. *J. Fungi.* 7(7), 555 (2021).

20. Tsukaguchi H, Tokui T, Mackenzie B, et al. A family of mammalian Na⁺-dependent L-ascorbic acid transporters. *Nature.* 399(6731), 70–75 (1999).


21. Ghahremani-Nasab M, Del Bakhshayesh AR, Akbari-Gharalari N, Mehdipour A. Biomolecular and cellular effects in skin wound healing: the association between ascorbic acid and hypoxia-induced factor. *J Biol Eng.* 17(1), 62 (2023).

22. Cho S, Chae JS, Shin H, et al. Hormetic dose response to L-ascorbic acid as an anti-cancer drug in colorectal cancer cell lines according to SVCT-2 expression. *Sci Rep.* 8(1), 11372 (2018).

23. Castellano-Pellicena I, Thornton MJ. Isolation of Epidermal Keratinocytes from Human Skin: The Scratch-Wound Assay for Assessment of Epidermal Keratinocyte Migration. *Methods Mol Biol.* 2154, 1-12 (2020).

24. Chong WT, Tan CP, Cheah YK, Lai OM. In-vitro and in-vivo evaluations of tocotrienol-rich nanoemulsified system on skin wound healing. *PLoS One.* 17(5), e0267381 (2022).

1
2
3 431 25. Chaitrakoonthong T, Ampornaramveth R, Kamolratanakul P. Rinsing with L-
4 432 Ascorbic Acid Exhibits Concentration-Dependent Effects on Human Gingival
5 433 Fibroblast In Vitro Wound Healing Behavior. *Int J Dent*. 2020, 4706418 (2020).
6 434
7 435 26. Yi Y, Wu M, Zhou X, *et al*. Ascorbic acid 2-glucoside preconditioning enhances
8 436 the ability of bone marrow mesenchymal stem cells in promoting wound healing.
9 437 *Stem Cell Res Ther*. 13(1), 119 (2022).
10 438
11 439 27. Savini I, Rossi A, Duranti G, Avigliano L, Catani MV, Melino G.
12 440 Characterization of Keratinocyte Differentiation Induced by Ascorbic Acid:
13 441 Protein Kinase C Involvement and Vitamin C. *J. Invest. Dermatol*. 118(2), 372–
14 442 379 (2002).
15 443
16 444 28. Egusa H, Nikawa H, Makihira S, Yatani H, Hamada T. In vitro mechanisms of
17 445 interleukin-8-mediated responses of human gingival epithelial cells to *Candida*
18 446 *albicans* infection. *Int. J. Med. Microbiol*. 296(4–5), 301–311 (2006).
19 447
20 448 29. Dongari-Bagtzoglou A, Kashleva H. Granulocyte-macrophage colony-
21 449 stimulating factor responses of oral epithelial cells to *Candida albicans*. *Oral*
22 450 *Microbiol Immunol*. 18(3), 165–170 (2003).
23 451
24 452 30. Griffiths JS, Camilli G, Kotowicz NK, Ho J, Richardson JP, Naglik JR. Role for
25 453 IL-1 Family Cytokines in Fungal Infections. *Front Microbiol*. 12, 633047 (2021).
26 454
27 455 31. Gao Y, Liang G, Wang Q, *et al*. Different Host Immunological Response to *C.*
28 456 *albicans* by Human Oral and Vaginal Epithelial Cells. *Mycopathologia*. 184(1),
29 457 1–12 (2019).
30 458
31 459 32. Kang JS, Kim HN, Jung DJ, *et al*. Regulation of UVB-Induced IL-8 and MCP-1
32 460 Production in Skin Keratinocytes by Increasing Vitamin C Uptake via the
33 461 Redistribution of SVCT-1 from the Cytosol to the Membrane. *J. Invest.*
34 462 *Dermatol*. 127(3), 698–706 (2007).
35 463
36 464 33. Bowie AG, O’Neill LAJ. Vitamin C Inhibits NF-κB Activation by TNF Via the
37 465 Activation of p38 Mitogen-Activated Protein Kinase. *J. Immunol*. 165(12), 7180–
38 466 7188 (2000).
39 467
40 468 34. Gęgotek A, Skrzydlewska E. Antioxidative and Anti-Inflammatory Activity of
41 469 Ascorbic Acid. *Antioxidants*. 11(10), 1993 (2022).
42 470
43 471 35. Ghalibaf MHE, Kianian F, Beigoli S, *et al*. The effects of vitamin C on
44 472 respiratory, allergic and immunological diseases: an experimental and clinical-
45 473 based review. *Inflammopharmacology*. 31(2), 653–672 (2023).
46 474
47 475 36. Cárcamo JM, Bórquez-Ojeda O, Golde DW. Vitamin C inhibits granulocyte
48 476 macrophage–colony-stimulating factor–induced signaling pathways. *Blood*.
49 477 99(9), 3205–3212 (2002).
50 478
51 479 37. Chen Y, Luo G, Yuan J, *et al*. Vitamin C Mitigates Oxidative Stress and Tumor
52 480 Necrosis Factor-Alpha in Severe Community-Acquired Pneumonia and LPS-
53 481 Induced Macrophages. *Mediators Inflamm*. 2014, 426740 (2014).
54 482
55 483 •• In this study a different model of infection was performed, in which
56 484 **vitamin C showed anti-inflammatory effect.**
57 485
58 486 38. Ness T, Abdallah M, Adams J, *et al*. *Candida albicans*-derived mannoproteins
59 487 activate NF-κB in reporter cells expressing TLR4, MD2 and CD14. *PLoS One*.
60 488 12(12), e0189939 (2017).
61 489
62 490 39. Lopes JP, Lionakis MS. Pathogenesis and virulence of *Candida albicans*.
63 491 *Virulence* 13(1), 89–121 (2022).
64 492
65 493
66 494
67 495
68 496
69 497
70 498
71 499
72 500
73 501
74 502
75 503
76 504
77 505
78 506
79 507
80 508
81 509
82 510
83 511
84 512
85 513
86 514
87 515
88 516
89 517
90 518
91 519
92 520
93 521
94 522
95 523
96 524
97 525
98 526
99 527
100 528



GRAPHICAL ABSTRACT

225x111mm (300 x 300 DPI)

Table 1: Oligonucleotide primer sequence

IL-8	FORWARD	TCCTGATTTCTGCAGCTCTG
	REVERSE	GTCCACTCTCAATCACTCTCAG
GM-CSF	FORWARD	ATGTGAATGCCATCCAGGAG
	REVERSE	CTTGTACAGCTCCAGGCG
IL-1β	FORWARD	TCTTCGACACATGGGATAACG
	REVERSE	GAGGTGGAGAGCTTTTCAGTTC
IL-6	FORWARD	AAAAGTCCTGATCCAGTTCCTG
	REVERSE	TGAGTTGTCATGTCCTGCAG
TNF-α	FORWARD	CTCACCCACACCATCAGC
	REVERSE	GAAGACCCCTCCCAGATAGA
IL-10	FORWARD	AGGATCAGCTGGACAACCTTG
	REVERSE	GATGTCTGGGTCTTGGTTCTC
18S	FORWARD	CGGCGACGACCCATTCTGAAC
	REVERSE	GAATCGAACCCTGATTCCCCGTC




Figure 1: Cell viability of oral keratinocytes after Vit C exposure for 3 h (A) and 24 h (B). Bars represent mean and SD values after the treatments. The dotted line (red) corresponds to the toxicity threshold (ISO 10993-5). Different letters indicate statistical differences between groups (A, Kruskal-Wallis and Dunn's post hoc tests, $p < 0.05$; B, one-way ANOVA and Tukey's post hoc test, $p < 0.05$).

495x218mm (300 x 300 DPI)




Figure 2: Analysis of cell migration or in vitro wound closure using oral keratinocytes (A) Mean data and SD error bars of the remaining scratch/gap area at 3, 24, 48 and 72 h. (B) Illustrations of the in vitro wound closure for each group at all the periods. The images were captured in an inverted microscope at 250X magnification. The asterisks (*) indicate statistical differences between control group and 0.1/1.2 mM of Vit C at 48 h and 0.6/1.2 mM of Vit C at 72 h (3, 24, 48h; one-way ANOVA and Dunnett's post hoc test, $p < 0.05$), (72 h; Kruskal-Wallis and Dunn's post hoc tests, $p < 0.05$).

96x116mm (300 x 300 DPI)




Figure 3: Effect of infection with *Candida albicans* for 7 h and treatment with Vit C for 6 h on IL-8 (A), GM-CSF (B), IL-1 β (C), IL-6 (D) and TNF- α (E) gene expression by oral keratinocytes. Bars represent mean and SD values after the different treatments. 18S was used as housekeeping gene. Different letters indicate statistical differences between groups (one-way ANOVA and Tukey's post hoc test, $p < 0.05$).

Apêndice C – Resultados de viabilidade celular da associação CAP + Vitamina C

A análise da viabilidade de queratinócitos orais expostos ao CAP, e posteriormente a Vitamina C, por 3 horas, indicou que a associação de tratamentos não reduz a viabilidade celular, com relação ao tratamento feito exclusivamente com o CAP. Ao contrário, o grupo exposto ao CAP e tratado com a maior concentração de Vitamina C, exibiu maior viabilidade celular ($p < 0.05$).




Figura 4: Gráfico representativo das médias e desvios-padrão dos dados de viabilidade celular após exposição de queratinócitos orais ao CAP e ao CAP seguido de VIT C, em diferentes concentrações, por 3 horas (Teste Kruskal-Wallis, comparações múltiplas (Letras diferentes indicam diferença estatística)).